Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry(dagger)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00070857" target="_blank" >RIV/65269705:_____/19:00070857 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1508672" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1508672</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2018.1508672" target="_blank" >10.1080/10428194.2018.1508672</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry(dagger)

Popis výsledku v původním jazyce

We analyzed 495 MCL patients from the Czech Lymphoma Study Group data registry. With the median follow-up of 4.4 years, 51.7% patients progressed or relapsed and 34.1% died. Five-year overall survival reached 65.3% and five-year progression free survival 44.1% of the patients. Maintenance rituximab (MR) after first line therapy improved overall and progression free survival compared to the patients under observation only (both p &lt; .001). Elevated beta-2-microglobulin (p = .003), presence of systemic symptoms (p = .002), ECOG &gt;0 (p = .003), age (p = .014), and MIPI (p &lt; .001) were associated with MR failure. Patients who did not achieve complete remission have had two-fold higher risk of MR failure (p &lt; .001). Autologous stem cell transplant reduced the risk of MR failure by 69% (p &lt; .001). The MIPI and the beta-2-microglobulin were identified as independent predictors of MR failure (p = .02 and p = .03, respectively). Patients who relapsed/progressed on MR reached shorter OS calculated from the MR start compared to patients without failure (HR = 15.0; p &lt; .001).

Název v anglickém jazyce

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry(dagger)

Popis výsledku anglicky

We analyzed 495 MCL patients from the Czech Lymphoma Study Group data registry. With the median follow-up of 4.4 years, 51.7% patients progressed or relapsed and 34.1% died. Five-year overall survival reached 65.3% and five-year progression free survival 44.1% of the patients. Maintenance rituximab (MR) after first line therapy improved overall and progression free survival compared to the patients under observation only (both p &lt; .001). Elevated beta-2-microglobulin (p = .003), presence of systemic symptoms (p = .002), ECOG &gt;0 (p = .003), age (p = .014), and MIPI (p &lt; .001) were associated with MR failure. Patients who did not achieve complete remission have had two-fold higher risk of MR failure (p &lt; .001). Autologous stem cell transplant reduced the risk of MR failure by 69% (p &lt; .001). The MIPI and the beta-2-microglobulin were identified as independent predictors of MR failure (p = .02 and p = .03, respectively). Patients who relapsed/progressed on MR reached shorter OS calculated from the MR start compared to patients without failure (HR = 15.0; p &lt; .001).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NV16-31092A" target="_blank" >NV16-31092A: Péče o nemocné staršího věku (?65 let) s Non-Hodgkinovými lymfomy – analýza faktorů ovlivňujících volbu léčby a osud nemocných</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

60

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

748-755

Kód UT WoS článku

000463704200024

EID výsledku v databázi Scopus

2-s2.0-85053256091